Wadzanai Samaneka

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

Susan E. Dorman, Payam Nahid, Ekaterina V. Kurbatova et al. · New England Journal of Medicine · 2021 · 551 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial

Susan E. Krown, Carlee Moser, Patrick MacPhail et al. · The Lancet · 2020 · 91 citations · Full text

Medicine, Infectious Diseases, Oncology +6

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial

Susan E. Dorman, Payam Nahid, Ekaterina V. Kurbatova et al. · Contemporary Clinical Trials · 2020 · 57 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Psychosocial Predictors of Non-Adherence and Treatment Failure in a Large Scale Multi-National Trial of Antiretroviral Therapy for HIV: Data from the ACTG A5175/PEARLS Trial

Steven A. Safren, Katie B. Biello, Laura Smeaton et al. · PLoS ONE · 2014 · 54 citations · Full text

Pharmacy, Health Sciences, Pharmacotherapy +17

Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults

Gregory P. Bisson, Ritesh Ramchandani, Sachiko Miyahara et al. · AIDS · 2017 · 48 citations · Full text

Public Health, Immunology, Infectious Diseases +14